Exhibit 99.3
PDL BioPharma, Inc.
Q2-2013
August 8, 2013
Following are some of the key points regarding PDL’s second quarter 2013 financial and business results.
Net Income
● | Net income for the second quarter of 2013 was $93.7 million, or $0.62 per diluted share, as compared with net income of $73.5 million, or $0.52 per diluted share, in the same quarter of 2012. The increase in net income in the second quarter is primarily due to the 14 percent increase in royalty revenues and the release of a tax liability of $5.7 million, which reduced the effective tax rate for the quarter. |
2013 Dividends
● | On June 12, 2013, PDL paid its second quarterly dividend in 2013 to stockholders of record, totaling $21 million and using earnings generated in the second quarter of 2013. The Board of Directors previously declared two remaining dividends for 2013, each of $0.15 per share of common stock, payable on September 12 and December 12 of 2013 to all stockholders who own shares of PDL on September 5 and December 5 of 2013, the record dates for each of the dividend payments, respectively. |
Updates on Approved Royalty Bearing Products
Avastin® (bevacizumab):
● | On July 25, 2013, Genentech/Roche reported that 1H13 worldwide sales increased by 12%. |
| | o | There was significant increase in US sales in colorectal cancer due to label expansion through multiple lines of therapy. |
| | o | Strong sales in EU were driven by ovarian and colorectal cancers, with the latter due to the label expansion through multiple lines of therapy. |
| | o | In Japan, sales increase was driven by steady growth in non-small cell lung cancer. |
● | Also on July 25, 2013, Genentech/Roche stated that it intends to file for approval for treatment of cervical cancer in US and EU in 2014. |
● | On December 12, 2012, and January 24, 2013, Genentech/Roche announced EU and US approval, respectively, for second-line metastatic colorectal cancer. |
Herceptin® (trastuzumab):
● | On July 25, 2013, Genentech/Roche reported that 1H13 worldwide sales increased by 5%. |
● | On June 28, 2013, Genentech/Roche said EMA’s CHMP issued a positive opinion recommending approval of a subcutaneous formulation of Herceptin to treat HER2-positive breast cancer. |
| | o | Subcutaneous administration takes 2-5 minutes instead of 30-90 minutes with the approved IV administration. |
Lucentis® (ranibizumab):
● | On July 25, 2013, Genentech/Roche reported that 1H13 US sales increased by 9%. |
| | o | Less frequent than monthly dosing regimen is stabilizing market share in AMD. |
| | o | RVO market share is stable and DME increased market share contributing to majority of Lucentis growth. |
● | On July 17, 2013, Novartis reported that 2Q13 ex-US sales decreased by 3%. |
| | o | Double digit volume growth offset by one-time price reductions required to secure reimbursement for new indications. |
| | o | Eylea launched in key EU countries. |
● | On July 5, 2013, Novartis announced that EU had expanded the label to include treatment for visual impairment due to choroidal neovascularization. |
| | o | Lucentis is first therapy to be approved for this indication in EU. |
Xolair® (omalizumab)
● | On July 25, 2013, Genentech/Roche reported that 1H13 US sales increased by 11%. |
● | On July 17, 2013, Novartis reported that 2Q13 ex-US sales increased by 20%. |
● | On June 26, 2013, Novartis announced that the second Phase 3 trial in 335 patients ages 12-75 with moderate to severe refractory chronic idiopathic urticaria (CIU) treated with 300 mg subcutaneous Xolair given every 4 weeks for 24 weeks as an add-on to antihistamine therapy met the primary efficacy endpoint with a similar incidence and severity of adverse events between treated and placebo patients. |
| | o | In February 2013, Novartis reported data from the first Phase 3 in 323 patients ages 12-75 with moderate to severe refractory CIU showing that 150 and 300 mg doses of Xolair as an add-on to antihistamine therapy each met the primary efficacy endpoint. |
● | On July 17, 2013, Novartis disclosed that it had filed for EU approval for CIU. |
| | o | Genentech/Roche is expected to file for approval of this indication in 2H13. |
PDL BioPharma, Inc.
Q2-2013
August 8, 2013
Actemra® (tocilizumab):
● | On July 25, 2013, Genentech/Roche reported that 1H13 worldwide sales increased by 33%. |
| | o | Sales growth was driven by monotherapy use with US being the biggest contributor to growth. |
● | On April 30, 2013, Genentech/Roche announced that FDA had approved its use for the treatment of a rare, debilitating condition in children known as polyarticular juvenile idiopathic arthritis. |
Perjeta™ (pertuzumab):
● | On July 25, 2013, Genentech/Roche reported 1H13 sales of CHF 108 million. |
● | Genentech/Roche announced EMA approval in March 2013. |
● | On July 1, 2013, Genentech/Roche announced that it had been granted priority review by FDA for use in neo-adjuvant setting for HER2+ breast cancer with PDUFA date of October 31, 2013. |
Kadcyla™ (TDM-1 or ado-trastuzumab emtansine):
● | On July 25, 2013, Genentech/Roche reported 1H13 sales of CHF 83 million. |
● | [Not Q2 but may be relevant to understand first bullet] On February 22, 2013, Genentech/Roche announced that FDA approval for second line treatment of HER2+ metastatic breast cancer and first line treatment for patients who relapse within 6 months following adjuvant therapy. |
● | Also on July 25, 2013, Genentech/Roche announced that a Phase 3 trial comparingKadcyla to the physician's choice of treatment in patients with HER2-positive breast cancer who have already been treated with a HER2-targeted therapy, met its co-primary endpoint of progression free survival. The other endpoint is overall survival, but these data are not yet mature. |
Updates on Select Development Stage Potential Royalty Bearing Products
Obinutuzumab:
● | On May 15, 2013, Genentech/Roche announced Phase 3 data from the CLL11 study to be presented at ASCO for the treatment of chronic lymphocytic leukemia (CLL). |
| | o | Announced marketing applications had been submitted to regulatory authorities including the European Medicines Association (EMA) and the FDA. |
| | o | Also announced, FDA designated it as a breakthrough therapy for CLL. |
| | o | Previously, Genentech/Roche announced that results from Stage 1 of a Phase 3 trial showed CLL patients treated with obinutuzumab + chlorambucil had a progression free survival (PFS) of 23 months compared to 10.9 months for patients treated with chlorambucil only. |
● | On July 2, 2013, Genentech/Roche announced that FDA accepted their Biologics License Application (BLA) and it had been granted priority review by FDA with a PDUFA date of December 20, 2013. |
● | On July 23, 2013, Genentech/Roche announced that results from planned interim analysis of Stage 2 of same Phase 3 trial showed CLL patients treated with obinutuzumab + chlorambucil lived significantly longer without disease worsening (PFS) than patients receiving Rituxan + chlorambucil. |
| | o | While the differences in PFS will not be disclosed until ASH in early December 2013, Genentech/Roche stated that the endpoint was achieved sooner than the target date of 2014 because of the magnitude of the difference between the two arms in Stage 2. |
Solanezumab:
● | On July 12, 2013, Lilly announced details regarding its new Phase 3 trial. |
| | o | 2,100 patients with mild Alzheimer’s Disease with amyloid pathology confirmed by either PET or cerebrospinal fluid instead of 1,322 mild Alzheimer’s Disease patients in previous Phase 3s. |
| | o | Co-primary endpoints of ADAS-Cog14 (cognition) and ADCS-iADL (function) instead of ADAS-Cog11 and ADCS-ADL used in previous Phase 3s. |
| | o | 22 months for patient enrollment beginning in September 2013 plus 18 month for patient follow up equals 40 months, or late 2016, to data. |
● | If solanezumab were to receive marketing authorization, PDL would receive a patent royalty of 3% through the expiration of Queen et al. patents in addition to a 12.5 year know-how royalty of 2% from date of first sale. |
PDL BioPharma, Inc.
Q2-2013
August 8, 2013
Forward-looking Statements
This document contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Important factors that could impair the value of the Company's royalty assets, restrict or impede the ability of the Company to invest in new income generating assets and limit the Company's ability to pay dividends are disclosed in the risk factors contained in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.
PDL BioPharma, Inc.
Q2-2013
August 8, 2013
Royalty Revenue by Product ($ in 000's) *
Avastin | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 33,234 | 46,720 | - | - | 79,953 |
2012 | 23,215 | 41,670 | 25,955 | 30,041 | 120,882 |
2011 | 22,283 | 41,967 | 23,870 | 22,886 | 111,006 |
2010 | 16,870 | 44,765 | 29,989 | 24,922 | 116,547 |
2009 | 13,605 | 35,161 | 21,060 | 15,141 | 84,966 |
2008 | 9,957 | 30,480 | 19,574 | 12,394 | 72,405 |
2007 | 8,990 | 21,842 | 17,478 | 9,549 | 57,859 |
2006 | 10,438 | 15,572 | 15,405 | 12,536 | 53,952 |
| | | | | | |
Herceptin | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 30,287 | 47,353 | - | - | 77,640 |
2012 | 25,702 | 44,628 | 30,433 | 28,307 | 129,070 |
2011 | 25,089 | 42,209 | 31,933 | 21,812 | 121,042 |
2010 | 23,402 | 38,555 | 27,952 | 25,441 | 115,350 |
2009 | 16,003 | 32,331 | 26,830 | 18,615 | 93,779 |
2008 | 14,092 | 34,383 | 28,122 | 20,282 | 96,880 |
2007 | 19,035 | 28,188 | 22,582 | 14,802 | 84,608 |
2006 | 15,142 | 19,716 | 21,557 | 20,354 | 76,769 |
| | | | | | |
Lucentis | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 12,032 | 30,066 | - | - | 42,097 |
2012 | 10,791 | 27,938 | 12,552 | 11,097 | 62,377 |
2011 | 8,878 | 24,313 | 12,157 | 10,750 | 56,099 |
2010 | 7,220 | 19,091 | 10,841 | 8,047 | 45,198 |
2009 | 4,621 | 12,863 | 8,123 | 6,152 | 31,759 |
2008 | 3,636 | 11,060 | 7,631 | 4,549 | 26,876 |
2007 | 2,931 | 6,543 | 6,579 | 3,517 | 19,570 |
2006 | - | - | 289 | 3,335 | 3,624 |
| | | | | | |
Xolair | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 5,930 | 10,025 | - | - | 15,955 |
2012 | 5,447 | 8,609 | 6,504 | 6,145 | 26,705 |
2011 | 4,590 | 7,621 | 5,916 | 5,823 | 23,949 |
2010 | 3,723 | 6,386 | 4,980 | 4,652 | 19,741 |
2009 | 2,665 | 5,082 | 4,085 | 3,722 | 15,553 |
2008 | 1,488 | 4,866 | 3,569 | 2,927 | 12,850 |
2007 | 1,684 | 3,942 | 3,332 | 2,184 | 11,142 |
2006 | 2,263 | 2,969 | 3,041 | 2,495 | 10,768 |
| | | | | | |
Perjeta | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 340 | 1,414 | - | - | 1,754 |
2012 | - | - | 58 | 250 | 308 |
2011 | - | - | - | - | - |
2010 | - | - | - | - | - |
2009 | - | - | - | - | - |
2008 | - | - | - | - | - |
2007 | - | - | - | - | - |
2006 | - | - | - | - | - |
| | | | | | |
Kadcyla | Q1 | Q2 | Q3 | Q4 | Total |
2013 | - | 551 | - | - | 551 |
2012 | - | - | - | - | - |
2011 | - | - | - | - | - |
2010 | - | - | - | - | - |
2009 | - | - | - | - | - |
2008 | - | - | - | - | - |
2007 | - | - | - | - | - |
2006 | - | - | - | - | - |
| | | | | | |
Tysabri | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 12,965 | 13,616 | - | - | 26,581 |
2012 | 11,233 | 12,202 | 11,749 | 12,255 | 47,439 |
2011 | 9,891 | 10,796 | 11,588 | 11,450 | 43,725 |
2010 | 8,791 | 8,788 | 8,735 | 9,440 | 35,754 |
2009 | 6,656 | 7,050 | 7,642 | 8,564 | 29,912 |
2008 | 3,883 | 5,042 | 5,949 | 6,992 | 21,866 |
2007 | 839 | 1,611 | 2,084 | 2,836 | 7,370 |
2006 | - | - | - | 237 | 237 |
| | | | | | |
Actemra | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 2,631 | 2,816 | - | - | 5,447 |
2012 | 1,705 | 2,074 | 2,145 | 2,462 | 8,385 |
2011 | 913 | 1,136 | 1,401 | 1,460 | 4,910 |
2010 | 1,587 | 237 | 315 | 688 | 2,827 |
2009 | 585 | 537 | 909 | 1,197 | 3,228 |
2008 | 44 | - | 146 | 369 | 559 |
2007 | 32 | - | - | 17 | 49 |
2006 | - | - | - | - | - |
* As reported to PDL by its licensees |
Totals may not sum due to rounding |
PDL BioPharma, Inc.
Q2-2013
August 8, 2013
Reported Net Sales Revenue by Product ($ in 000's) *
Avastin | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 1,653,108 | 1,694,678 | - | - | 3,347,786 |
2012 | 1,502,757 | 1,573,727 | 1,551,327 | 1,662,977 | 6,290,788 |
2011 | 1,597,461 | 1,582,705 | 1,581,095 | 1,469,994 | 6,231,255 |
2010 | 1,506,788 | 1,596,892 | 1,594,707 | 1,646,218 | 6,344,605 |
2009 | 1,345,487 | 1,295,536 | 1,439,730 | 1,514,053 | 5,594,806 |
2008 | 980,715 | 1,084,930 | 1,180,427 | 1,239,382 | 4,485,454 |
2007 | 678,068 | 746,587 | 797,013 | 875,084 | 3,096,752 |
2006 | 439,318 | 516,052 | 570,551 | 592,897 | 2,118,817 |
| | | | | | |
Herceptin | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 1,681,574 | 1,744,145 | - | - | 3,425,718 |
2012 | 1,515,255 | 1,625,313 | 1,663,695 | 1,650,495 | 6,454,759 |
2011 | 1,391,568 | 1,559,975 | 1,642,898 | 1,432,771 | 6,027,211 |
2010 | 1,270,846 | 1,349,512 | 1,300,934 | 1,409,310 | 5,330,602 |
2009 | 1,210,268 | 1,133,993 | 1,226,435 | 1,278,626 | 4,849,323 |
2008 | 1,105,426 | 1,195,215 | 1,211,982 | 1,186,806 | 4,699,428 |
2007 | 891,761 | 949,556 | 979,602 | 1,015,033 | 3,835,952 |
2006 | 529,585 | 659,719 | 761,099 | 803,576 | 2,753,979 |
| | | | | | |
Lucentis | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 1,203,179 | 1,171,423 | - | - | 2,374,602 |
2012 | 1,079,092 | 1,086,543 | 1,097,541 | 1,109,695 | 4,372,871 |
2011 | 887,757 | 943,418 | 1,052,809 | 1,075,015 | 3,958,999 |
2010 | 721,967 | 698,890 | 745,376 | 804,684 | 2,970,917 |
2009 | 462,103 | 469,736 | 555,296 | 615,212 | 2,102,347 |
2008 | 363,615 | 393,682 | 460,167 | 454,922 | 1,672,386 |
2007 | 224,820 | 219,579 | 299,995 | 322,300 | 1,066,695 |
2006 | - | - | 10,689 | 157,742 | 168,431 |
| | | | | | |
Xolair | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 341,309 | 365,778 | - | - | 707,088 |
2012 | 310,234 | 314,638 | 347,796 | 340,431 | 1,313,100 |
2011 | 267,754 | 277,642 | 310,874 | 314,911 | 1,171,182 |
2010 | 228,859 | 225,878 | 251,055 | 263,389 | 969,179 |
2009 | 184,669 | 181,086 | 211,006 | 219,693 | 796,454 |
2008 | 137,875 | 169,521 | 177,179 | 183,753 | 668,329 |
2007 | 129,172 | 130,700 | 144,250 | 147,754 | 551,876 |
2006 | 95,241 | 99,354 | 112,608 | 118,002 | 425,204 |
| | | | | | |
Perjeta | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 34,008 | 55,076 | - | - | 89,084 |
2012 | - | - | 5,080 | 25,000 | 30,079 |
2011 | - | - | - | - | - |
2010 | - | - | - | - | - |
2009 | - | - | - | - | - |
2008 | - | - | - | - | - |
2007 | - | - | - | - | - |
2006 | - | - | - | - | - |
| | | | | | |
Kadcyla | Q1 | Q2 | Q3 | Q4 | Total |
2013 | - | 21,459 | - | - | 21,459 |
2012 | - | - | - | - | - |
2011 | - | - | - | - | - |
2010 | - | - | - | - | - |
2009 | - | - | - | - | - |
2008 | - | - | - | - | - |
2007 | - | - | - | - | - |
2006 | - | - | - | - | - |
| | | | | | |
Tysabri | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 434,677 | 451,358 | - | - | 886,035 |
2012 | 374,430 | 401,743 | 391,623 | 408,711 | 1,576,508 |
2011 | 329,696 | 356,876 | 388,758 | 381,618 | 1,456,948 |
2010 | 293,047 | 287,925 | 293,664 | 316,657 | 1,191,292 |
2009 | 221,854 | 229,993 | 257,240 | 285,481 | 994,569 |
2008 | 129,430 | 163,076 | 200,783 | 233,070 | 726,359 |
2007 | 30,468 | 48,715 | 71,972 | 94,521 | 245,675 |
2006 | - | - | - | 7,890 | 7,890 |
| | | | | | |
Actemra | Q1 | Q2 | Q3 | Q4 | Total |
2013 | 87,703 | 91,374 | - | - | 179,077 |
2012 | 56,662 | 66,624 | 71,505 | 82,053 | 276,843 |
2011 | 30,433 | 35,370 | 46,709 | 48,671 | 161,183 |
2010 | 52,908 | 5,405 | 10,493 | 22,919 | 91,725 |
2009 | 19,504 | 17,920 | 30,313 | 39,888 | 107,625 |
2008 | 1,452 | 1,377 | 5,981 | 12,305 | 21,115 |
2007 | - | - | - | 1,137 | 1,137 |
2006 | - | - | - | - | - |
| | | | | | |
* As reported to PDL by its licensees |
Totals may not sum due to rounding |
PDL BioPharma, Inc.
Q2-2013
August 8, 2013
Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *
Avastin Sales | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 |
US Made & Sold | 652,824 | 724,483 | 679,914 | 710,501 | 664,109 | 750,491 |
US Made & ex-US Sold | 448,037 | 532,979 | 428,976 | 281,905 | 161,369 | 165,651 |
ex-US Made & Sold | 401,896 | 316,265 | 442,437 | 670,572 | 827,629 | 778,536 |
Total | 1,502,757 | 1,573,727 | 1,551,327 | 1,662,977 | 1,653,108 | 1,694,678 |
US Made & Sold | 43% | 46% | 44% | 43% | 40% | 44% |
US Made & ex-US Sold | 30% | 34% | 28% | 17% | 10% | 10% |
ex-US Made & Sold | 27% | 20% | 29% | 40% | 50% | 46% |
| | | | | | | |
Herceptin Sales | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 |
US Made & Sold | 456,920 | 497,109 | 503,612 | 515,790 | 514,113 | 583,677 |
US Made & ex-US Sold | 523,353 | 466,477 | 545,625 | 552,127 | 486,400 | 563,243 |
ex-US Made & Sold | 534,982 | 661,727 | 614,459 | 582,578 | 681,060 | 597,225 |
Total | 1,515,255 | 1,625,313 | 1,663,695 | 1,650,495 | 1,681,574 | 1,744,145 |
US Made & Sold | 30% | 31% | 30% | 31% | 31% | 33% |
US Made & ex-US Sold | 35% | 29% | 33% | 33% | 29% | 32% |
ex-US Made & Sold | 35% | 41% | 37% | 35% | 41% | 34% |
| | | | | | | |
Lucentis Sales | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 |
US Made & Sold | 433,428 | 412,131 | 385,746 | 381,592 | 392,207 | 419,030 |
US Made & ex-US Sold | 645,665 | 674,411 | 711,795 | 728,103 | 810,972 | 752,393 |
ex-US Made & Sold | - | - | - | - | - | - |
Total | 1,079,092 | 1,086,543 | 1,097,541 | 1,109,695 | 1,203,179 | 1,171,423 |
US Made & Sold | 40% | 38% | 35% | 34% | 33% | 36% |
US Made & ex-US Sold | 60% | 62% | 65% | 66% | 67% | 64% |
ex-US Made & Sold | 0% | 0% | 0% | 0% | 0% | 0% |
| | | | | | | |
Xolair Sales | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 |
US Made & Sold | 185,505 | 193,600 | 211,702 | 210,892 | 207,976 | 218,860 |
US Made & ex-US Sold | - | - | - | - | - | - |
ex-US Made & Sold | 124,729 | 121,039 | 136,094 | 129,540 | 133,333 | 146,918 |
Total | 310,234 | �� 314,638 | 347,796 | 340,431 | 341,309 | 365,778 |
US Made & Sold | 60% | 62% | 61% | 62% | 61% | 60% |
US Made & ex-US Sold | 0% | 0% | 0% | 0% | 0% | 0% |
ex-US Made & Sold | 40% | 38% | 39% | 38% | 39% | 40% |
| | | | | | | |
Perjeta Sales | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 |
US Made & Sold | - | - | 5,080 | 24,571 | 32,377 | 48,979 |
US Made & ex-US Sold | - | - | - | 428 | 1,632 | 6,096 |
ex-US Made & Sold | - | - | - | - | - | - |
Total | - | - | 5,080 | 25,000 | 34,008 | 55,076 |
US Made & Sold | 0% | 0% | 100% | 98% | 95% | 89% |
US Made & ex-US Sold | 0% | 0% | 0% | 2% | 5% | 11% |
ex-US Made & Sold | 0% | 0% | 0% | 0% | 0% | 0% |
| | | | | | | |
Kadcyla Sales | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 |
US Made & Sold | - | - | - | - | - | 21,459 |
US Made & ex-US Sold | - | - | - | - | - | - |
ex-US Made & Sold | - | - | - | - | - | - |
Total | - | - | - | - | - | 21,459 |
US Made & Sold | 0% | 0% | 0% | 0% | 0% | 100% |
US Made & ex-US Sold | 0% | 0% | 0% | 0% | 0% | 0% |
ex-US Made & Sold | 0% | 0% | 0% | 0% | 0% | 0% |
| | | | | | | |
Total Sales | 2012 - Q1 | 2012 - Q2 | 2012 - Q3 | 2012 - Q4 | 2013 - Q1 | 2013 - Q2 |
US Made & Sold | 1,728,678 | 1,827,323 | 1,786,053 | 1,843,345 | 1,810,783 | 2,042,496 |
US Made & ex-US Sold | 1,617,054 | 1,673,867 | 1,686,395 | 1,562,564 | 1,460,373 | 1,487,383 |
ex-US Made & Sold | 1,061,607 | 1,099,031 | 1,192,990 | 1,382,690 | 1,642,023 | 1,522,679 |
Total | 4,407,339 | 4,600,221 | 4,665,438 | 4,788,598 | 4,913,178 | 5,052,559 |
US Made & Sold | 39% | 40% | 38% | 38% | 37% | 40% |
US Made & ex-US Sold | 37% | 36% | 36% | 33% | 30% | 29% |
ex-US Made & Sold | 24% | 24% | 26% | 29% | 33% | 30% |
| | | | | | | |
* As reported to PDL by its licensees |
Totals may not sum due to rounding |
Page 6
